Genetics testing company Visible Genomics has launched a new non-invasive genetic eye test that determines a patient’s likelihood of contracting Age-Related Macular Degeneration (AMD). AMD affects the macular, the central part of the retina, and is one of the leading causes of irreversible vision loss in the United States, affecting over 11 million Americans. It is estimated that up to 70% of AMD cases are due to genetics.
Visible Genomics recommends the test for those who have a family history of the disease, or those showing signs of early or intermediate AMD, which are the highest group risks for progressing to advanced stages of AMD with vision loss. The goal of the test is to help doctors and their patients take preventative and proactive care of their vision. The clinically-validated saliva-based test combines a person’s genetic status, ocular findings, and demographic and lifestyle characteristics to deliver a comprehensive and clinically actionable risk assessment. This assessment determines the AMD patient’s progression risk of developing advanced AMD, and predicts the lifetime risk for those with a family member with AMD.
“Age-related macular degeneration is one of the leading causes of blindness in the United States, yet there’s a lack of accessible and reliable genetic risk testing options that can help with proper diagnosis and prognosis,” stated Visible Genomics CEO and Founder, Frank Adamo, adding, “Our healthcare system is reactive instead of proactive and preventative. With the use of the Visible Genomics testing system, we can now give doctors and their patients the right tools to help prevent vision loss.”
Dr. Barry Eiden, OD, FAAO, President and Medical Director of North Suburban Vision Consultants, Ltd has been using the Visible Genomics testing system for his patients. “The results provided with earlier intervention, lead to a better prognosis and outcome. We’re now able to create a personalized patient management plan, and take the proper steps by delaying disease onset or slowing disease progression,” said Eiden. Traditionally, patients who were at risk of developing AMD or progressing to advanced stages of AMD have had no advance awareness of its probability and were diagnosed only after severe symptoms had surfaced.